With 0.98 million shares changed hands, the volume of the stock remained lighter than its average volume of 6.9 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.8999 whereas the lowest price it dropped to was $0.82. The 52-week range on PMN shows that it touched its highest point at $1.75 and its lowest point at $0.38 during that stretch. It currently has a 1-year price target of $6.10. Beta for the stock currently stands at 0.04.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PMN was up-trending over the past week, with a rise of 2.46%, but this was up by 74.95% over a month. Three-month performance surged to 39.30% while six-month performance fell -4.96%. The stock lost -11.36% in the past year, while it has lost -58.36% so far this year. A look at the trailing 12-month EPS for PMN yields -0.04 with Next year EPS estimates of -0.52. For the next quarter, that number is -0.17. This implies an EPS growth rate of -628.60% for this year and 10.15% for next year.
Float and Shares Shorts:
At present, 32.69 million PMN shares are outstanding with a float of 23.12 million shares on hand for trading. On 2025-07-15, short shares totaled 1.77 million, which was 541.0 higher than short shares on 1749772800. In addition to Mr. Eugene W. Williams as the firm’s Co-Founder & Chairman, Mr. Neil K. Warma M.B.A. serves as its CEO, President, Compliance Officer & Director.
Institutional Ownership:
Through their ownership of 0.28797 of PMN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, PMN reported revenue of $0.0 and operating income of -$7460095.0. The EBITDA in the recently reported quarter was -$7347903.0 and diluted EPS was -$0.21.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With PMN analysts setting a high price target of 9.442023 and a low target of 3.0521653, the average target price over the next 12 months is 6.105057. Based on these targets, PMN could surge 1024.05% to reach the target high and rise by 263.35% to reach the target low. Reaching the average price target will result in a growth of 626.79% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.07909495 being high and -$0.07909495 being low. For PMN, this leads to a yearly average estimate of -$0.07909495.
